चिकित्सा प्रत्यारोपण एवं सर्जरी

खुला एक्सेस

हमारा समूह 1000 से अधिक वैज्ञानिक सोसायटी के सहयोग से हर साल संयुक्त राज्य अमेरिका, यूरोप और एशिया में 3000+ वैश्विक सम्मेलन श्रृंखला कार्यक्रम आयोजित करता है और 700+ ओपन एक्सेस जर्नल प्रकाशित करता है जिसमें 50000 से अधिक प्रतिष्ठित व्यक्तित्व, प्रतिष्ठित वैज्ञानिक संपादकीय बोर्ड के सदस्यों के रूप में शामिल होते हैं।

ओपन एक्सेस जर्नल्स को अधिक पाठक और उद्धरण मिल रहे हैं
700 जर्नल और 15,000,000 पाठक प्रत्येक जर्नल को 25,000+ पाठक मिल रहे हैं

में अनुक्रमित
  • गूगल ज्ञानी
  • RefSeek
  • हमदर्द विश्वविद्यालय
  • ईबीएससीओ एज़
  • पबलोन्स
  • आईसीएमजेई
इस पृष्ठ को साझा करें

अमूर्त

Patients with Head and Neck Cancer Undergoing Reconstructive Surgery

Nitika Goel

In the last two decades, there have been several changes in the field of head and neck surgery. Reconstructions using microvascular free flaps completely replaced earlier methods. More significantly, there has been a paradigm change toward attempting to re-establish normal function and appearance in addition to reliable wound closure to safeguard key structures. Using an evidence-based strategy whenever possible, the current research will propose an algorithmic approach to head and neck reconstruction of diverse subsites.

In contrast to typical cytotoxic therapies, which often cause cell loss, molecular therapeutics are a targeted approach to treating malignancies that express the epidermal growth factor receptor (EGFR). However, the early excitement for this focused treatment has been dampened by the discovery that resistance to such therapy is widespread in clinical studies. However, a deeper knowledge of the molecular mechanisms underlying various receptor tyrosine kinases that are known to be active in cancer has shown a rich network of cross-talk between receptor pathways, with a crucial discovery being shared downstream signalling pathways. Such interactions could be a major factor in the resistance to EGFR-directed treatment. In the context of squamous cell cancer of the head and neck, a tumour that is known to be primarily driven by EGFR-related oncogenic signals, we review the interaction between EGFR and Met and the type 1 insulin-like growth factor receptor (IGF-1R) tyrosine kinases as well as their contribution to anti-EGFR therapeutic resistance in this article.